Cargando…
Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
Bladder cancer (BC) is a common urological cancer of high mortality and recurrence rates. Currently, cystoscopy is performed as standard examination for the diagnosis and subsequent monitoring for recurrence of the patients. Frequent expensive and invasive procedures may deterrent patients from regu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452537/ https://www.ncbi.nlm.nih.gov/pubmed/36071106 http://dx.doi.org/10.1038/s41598-022-19576-9 |
_version_ | 1784784931577135104 |
---|---|
author | Nizioł, Joanna Ossoliński, Krzysztof Płaza-Altamer, Aneta Kołodziej, Artur Ossolińska, Anna Ossoliński, Tadeusz Ruman, Tomasz |
author_facet | Nizioł, Joanna Ossoliński, Krzysztof Płaza-Altamer, Aneta Kołodziej, Artur Ossolińska, Anna Ossoliński, Tadeusz Ruman, Tomasz |
author_sort | Nizioł, Joanna |
collection | PubMed |
description | Bladder cancer (BC) is a common urological cancer of high mortality and recurrence rates. Currently, cystoscopy is performed as standard examination for the diagnosis and subsequent monitoring for recurrence of the patients. Frequent expensive and invasive procedures may deterrent patients from regular follow-up screening, therefore it is important to look for new non-invasive methods to aid in the detection of recurrent and/or primary BC. In this study, ultra-high-performance liquid chromatography coupled with ultra-high-resolution mass spectrometry was employed for non-targeted metabolomic profiling of 200 human serum samples to identify biochemical signatures that differentiate BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation revealed twenty-seven metabolites that differentiate between BC patients from NCs. Abundances of these metabolites displayed statistically significant differences in two independent training and validation sets. Twenty-three serum metabolites were also found to be distinguishing between low- and high-grade of BC patients and controls. Thirty-seven serum metabolites were found to differentiate between different stages of BC. The results suggest that measurement of serum metabolites may provide more facile and less invasive diagnostic methodology for detection of bladder cancer and recurrent disease management. |
format | Online Article Text |
id | pubmed-9452537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-94525372022-09-09 Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer Nizioł, Joanna Ossoliński, Krzysztof Płaza-Altamer, Aneta Kołodziej, Artur Ossolińska, Anna Ossoliński, Tadeusz Ruman, Tomasz Sci Rep Article Bladder cancer (BC) is a common urological cancer of high mortality and recurrence rates. Currently, cystoscopy is performed as standard examination for the diagnosis and subsequent monitoring for recurrence of the patients. Frequent expensive and invasive procedures may deterrent patients from regular follow-up screening, therefore it is important to look for new non-invasive methods to aid in the detection of recurrent and/or primary BC. In this study, ultra-high-performance liquid chromatography coupled with ultra-high-resolution mass spectrometry was employed for non-targeted metabolomic profiling of 200 human serum samples to identify biochemical signatures that differentiate BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation revealed twenty-seven metabolites that differentiate between BC patients from NCs. Abundances of these metabolites displayed statistically significant differences in two independent training and validation sets. Twenty-three serum metabolites were also found to be distinguishing between low- and high-grade of BC patients and controls. Thirty-seven serum metabolites were found to differentiate between different stages of BC. The results suggest that measurement of serum metabolites may provide more facile and less invasive diagnostic methodology for detection of bladder cancer and recurrent disease management. Nature Publishing Group UK 2022-09-07 /pmc/articles/PMC9452537/ /pubmed/36071106 http://dx.doi.org/10.1038/s41598-022-19576-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Nizioł, Joanna Ossoliński, Krzysztof Płaza-Altamer, Aneta Kołodziej, Artur Ossolińska, Anna Ossoliński, Tadeusz Ruman, Tomasz Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer |
title | Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer |
title_full | Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer |
title_fullStr | Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer |
title_full_unstemmed | Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer |
title_short | Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer |
title_sort | untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452537/ https://www.ncbi.nlm.nih.gov/pubmed/36071106 http://dx.doi.org/10.1038/s41598-022-19576-9 |
work_keys_str_mv | AT niziołjoanna untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer AT ossolinskikrzysztof untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer AT płazaaltameraneta untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer AT kołodziejartur untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer AT ossolinskaanna untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer AT ossolinskitadeusz untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer AT rumantomasz untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer |